17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT00119236 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: tanespimycin
DRUG: irinotecan hydrochloride

Sponsor

National Cancer Institute (NCI)